Department of Pharmacology and Chemical Biology, Emory University, Atlanta, GA, USA.
Department of Neurology, Emory University, Atlanta, GA, USA.
Neuroscience. 2023 May 1;517:37-49. doi: 10.1016/j.neuroscience.2023.02.020. Epub 2023 Mar 4.
Although the mechanisms underlying dystonia are largely unknown, dystonia is often associated with abnormal dopamine neurotransmission. DOPA-responsive dystonia (DRD) is a prototype disorder for understanding dopamine dysfunction in dystonia because it is caused by mutations in genes necessary for the synthesis of dopamine and alleviated by the indirect-acting dopamine agonist l-DOPA. Although adaptations in striatal dopamine receptor-mediated intracellular signaling have been studied extensively in models of Parkinson's disease, another movement disorders associated with dopamine deficiency, little is known about dopaminergic adaptations in dystonia. To identify the dopamine receptor-mediated intracellular signaling associated with dystonia, we used immunohistochemistry to quantify striatal protein kinase A activity and extracellular signal-related kinase (ERK) phosphorylation after dopaminergic challenges in a knockin mouse model of DRD. l-DOPA treatment induced the phosphorylation of both protein kinase A substrates and ERK largely in D1 dopamine receptor-expressing striatal neurons. As expected, this response was blocked by pretreatment with the D1 dopamine receptor antagonist SCH23390. The D2 dopamine receptor antagonist raclopride also significantly reduced the phosphorylation of ERK; this contrasts with models of parkinsonism in which l-DOPA-induced ERK phosphorylation is not mediated by D2 dopamine receptors. Further, the dysregulated signaling was dependent on striatal subdomains whereby ERK phosphorylation was largely confined to dorsomedial (associative) striatum while the dorsolateral (sensorimotor) striatum was unresponsive. This complex interaction between striatal functional domains and dysregulated dopamine-receptor mediated responses has not been observed in other models of dopamine deficiency, such as parkinsonism, suggesting that regional variation in dopamine-mediated neurotransmission may be a hallmark of dystonia.
虽然导致肌张力障碍的机制在很大程度上尚不清楚,但肌张力障碍通常与异常的多巴胺神经传递有关。多巴反应性肌张力障碍(DRD)是理解肌张力障碍中多巴胺功能障碍的典型疾病,因为它是由多巴胺合成所必需的基因突变引起的,并且可以通过间接作用的多巴胺激动剂 l-DOPA 缓解。虽然在帕金森病的模型中已经广泛研究了纹状体多巴胺受体介导的细胞内信号转导的适应性,但对于与多巴胺缺乏相关的另一种运动障碍——肌张力障碍,关于多巴胺能适应性的了解甚少。为了确定与肌张力障碍相关的多巴胺受体介导的细胞内信号转导,我们使用免疫组织化学方法,在 DRD 的基因敲入小鼠模型中,量化了多巴胺能刺激后纹状体蛋白激酶 A 活性和细胞外信号调节激酶(ERK)磷酸化。l-DOPA 治疗诱导了蛋白激酶 A 底物和 ERK 的磷酸化,主要在表达 D1 多巴胺受体的纹状体神经元中。正如预期的那样,这种反应被 D1 多巴胺受体拮抗剂 SCH23390 的预处理所阻断。D2 多巴胺受体拮抗剂氯丙嗪也显著降低了 ERK 的磷酸化;这与帕金森病模型形成对比,在帕金森病模型中,l-DOPA 诱导的 ERK 磷酸化不是由 D2 多巴胺受体介导的。此外,失调的信号转导依赖于纹状体亚域,其中 ERK 磷酸化主要局限于背内侧(联想)纹状体,而背外侧(感觉运动)纹状体没有反应。这种纹状体功能域之间的复杂相互作用以及多巴胺受体介导的反应失调在其他多巴胺缺乏模型中尚未观察到,例如帕金森病,这表明多巴胺介导的神经传递的区域变化可能是肌张力障碍的标志。